Is NCT07546760 recruiting in Rialto, CA?

Yes, NCT07546760 is currently recruiting participants at its Rialto, CA location. This hepatic impairment clinical trial is actively enrolling qualified participants.

How do I join the hepatic impairment clinical trial in Rialto?

To join this clinical trial in Rialto, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Rialto clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Hepatic Impairment Clinical Trial in Rialto, CA

Who Can Participate

Inclusion Criteria

Age 18-85 years at consent.

Healthy controls: Medically healthy; no clinically significant findings in history, exam, labs, vitals, or 12 lead ECG (per investigator).

Hepatic impairment: Chronic (≥6 months), stable; documented Child Pugh B (Group 2) or C (Group 1).

Stable concomitant regimen ≥2 weeks before screening (Groups 1-2).

T2DM allowed if HbA1c \<10% and no severe hypo/hyperglycaemia or hospitalisation within 6 months.

Body weight ≥50 kg; BMI 18-42 kg/m².

Sex assigned at birth (male/female); contraception per local regulations. Females of child bearing potential: negative pregnancy tests and condoms plus one highly effective method through 54 days post last dose. Males: condom use; no sperm donation through 54 days post last dose.

Written informed consent; separate consent for optional genomics.

Exclusion Criteria

Healthy controls only:

Any clinically significant disease; Diabetes;

lab values i) ALT/AST/ALP \>1.5×ULN; ii) WBC/platelets \<LLN; iii) haemoglobin \<11.0 g/dL (female) or \<12.0 g/dL (male); aPTT or PT/INR \>1.2×ULN; iv) total bilirubin \>1.5×ULN (or Gilbert's);

abnormal resting vital signs i) SBP \>150 or \<90 mmHg, ii) DBP \>95 or \<50 mmHg, iii) pulse ≥100 or ≤45 bpm;

QTcF \>450 ms or clinically significant ECG abnormalities;

severe allergy/hypersensitivity;

major surgery within 30 days;

pancreatitis or pancreatic enzymes \>2×ULN;

triglycerides \>500 mg/dL (5.6 mmol/L);

calcitonin \>50 ng/L (50 pg/mL);

severe vitamin D deficiency (\<12 ng/mL, 30 nmol/L);

low corrected or ionised calcium;

HIV positive; HBV surface/core Ab or HCV Ab positive; drug/alcohol abuse within 1 year. Hepatically impaired only:

Unstable medical/psychological conditions or uncontrolled systemic disease;

eGFR \<50 mL/min/1.73 m² (CKD EPI 2021);

Abnormal resting vital signs i) SBP \>160 or \<100 mmHg, ii) DBP \>110 or \<65 mmHg, iii) pulse ≥100 or ≤50 bpm;

platelets \<35×10⁹/L; neutrophils \<1.2×10⁹/L; haemoglobin \<85 g/L; HbA1c ≥10%;

oesophageal banding within 3 months or GI bleeding within 6 months;

ascites requiring paracentesis and albumin ≤4 week intervals; paracentesis within 30 days;

fluctuating/worsening hepatic function during screening; hepatocellular carcinoma;

acute liver disease due to infection/drug; hepatic impairment due to non liver disease;

biliary obstruction or non parenchymal causes; hepatic encephalopathy Grade ≥2;

functioning organ transplant or anticipated within 2 months; prior porto systemic shunt/TIPS;

QTcF \>480 ms or clinically significant ECG abnormalities;

pancreatitis or pancreatic enzymes \>2×ULN;

triglycerides \>500 mg/dL (5.6 mmol/L); calcitonin \>50 ng/L (50 pg/mL); severe vitamin D deficiency (\<12 ng/mL, 30 nmol/L); ionised calcium \<LLN;

neoplastic disease within 10 years (except adequately treated BCC/SCC or in situ cervical); MEN2 or medullary thyroid carcinoma (personal or first degree relative); significant gastric emptying abnormality;

HIV positive; HBV surface/core Ab or HCV Ab positive (may be included if HBV DNA or HCV RNA negative on follow up); drug/alcohol abuse within 1 year.

Exposure to a new chemical entity within 30 days or 5 half lives (whichever longer) before intervention; prior exposure to AZD9550 or AZD6234; Prior/concomitant therapy: Healthy controls:

use of prescription/non prescription/supplements within 7 days (or 14 days for enzyme inducers) or 5 half lives before intervention unless judged non interfering; current oral contraceptives or oestrogen HRT. Hepatically impaired:

prohibited-weight loss medicines (including GLP 1), agents causing significant weight gain (e.g., systemic glucocorticoids, antipsychotics), GLP 1 RAs for diabetes, QT prolonging/prokinetic agents, oral contraceptives for contraception; restricted-short systemic glucocorticoids (≤7 days), 5HT 3 antiemetics at lowest effective dose, combined oral contraceptives for non contraceptive indications. If diabetes develops and requires insulin/SU/GLP 1 RA, discontinue from study. Other:

prior enrolment in this study (screened without dosing permitted). Positive drugs of abuse and/or alcohol screen (except prescribed meds in hepatic impairment); recent blood products/donation per protocol thresholds; employees or close relatives; vulnerable populations; unlikely to comply (investigator judgement).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rialto?

Yes, this clinical trial (NCT07546760) has an active research site in Rialto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatic Impairment Treatment Options in Rialto, CA

If you're searching for hepatic impairment treatment options in Rialto, CA, this clinical trial (NCT07546760) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rialto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatic impairment specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatic impairment clinical trials near you to find additional studies recruiting in your area.

Hepatic Impairment Clinical Trial in Rialto, CA

Expert Care in Rialto

IRB Approved

No-Cost Care

Apply for This Rialto Location

Why Participate?

Simple Process

About This Hepatic Impairment Study in Rialto